Want to see GRI full AI Analyst Report?
Top Page
GRI Bio
(NASDAQ:GRI)
Select Model
Select Model
Rating:54Neutral
Price Target:
$1.50
▼(-21.47% Downside)
Action:Reiterated
Date:09/09/26
The score is held back primarily by weak financial performance (no revenue, ongoing losses, and deepening cash burn), which implies continued reliance on external funding. Offsetting this are constructive corporate catalysts (Orphan Drug Designation and positive Phase 2a biomarker data) and a neutral-to-mildly improving technical setup, while valuation provides little support due to negative earnings and no dividend.
Positive Factors
Clinical differentiation
Positive Phase 2a signals across clinical and biological endpoints, together with favorable safety findings, strengthen the case for GRI-0621 as a differentiated IPF candidate. This can support continued development, patient adoption, and partnership interest if later-stage results remain consistent.
Negative Factors
Pre-commercial business model
The absence of product revenue means GRI Bio has not yet demonstrated a commercial funding engine and remains dependent on advancing candidates toward approval. Until a therapy is launched or a partnership generates payments, operating needs must be supported primarily by external capital.
Read all positive and negative factors
Positive Factors
Negative Factors
Clinical differentiation
Positive Phase 2a signals across clinical and biological endpoints, together with favorable safety findings, strengthen the case for GRI-0621 as a differentiated IPF candidate. This can support continued development, patient adoption, and partnership interest if later-stage results remain consistent.
Read all positive factors
GRI Bio (GRI) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$3.21M
Dividend YieldN/A
Average Volume (3M)80.80K
Price to Earnings (P/E)―
Beta (1Y)2.54
Revenue GrowthN/A
EPS Growth93.96%
CountryUS
Employees4
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-80.38
Shares Outstanding2,186,115
10 Day Avg. Volume42,232
30 Day Avg. Volume80,795
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.11
Price to Sales (P/S)0.00
P/FCF Ratio-0.07
Enterprise Value/Market Cap-2.40
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit3.85K
Enterprise Value/Ebitda0.61
Forecast
1Y Price Target
$27.00Price Target Upside1313.61% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-3.9
Revenue Forecast (FY)N/A
GRI Bio Business Overview & Revenue Model
Company Description
GRI Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies that target diseases leading to inflammatory, fibrotic, and autoimmune disorders in the United States. Its lead product ca...
How the Company Makes Money
GRI Bio’s business model is typical of a clinical-stage biotech: it primarily uses external capital and collaboration economics to fund research and development rather than generating material recurring revenue from product sales. Potential and/or...
GRI Bio Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
58
Neutral
Cash Flow
18
Very Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Mar 2024 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -2.00K | -4.00K | 0.00 | 0.00 | 0.00 | 0.00 |
| EBITDA | -12.57M | -11.97M | -8.23M | -10.95M | -2.56M | -989.00K |
| Net Income | -12.55M | -11.96M | -8.21M | -13.04M | -3.22M | -1.56M |
Balance Sheet | ||||||
| Total Assets | 11.38M | 8.67M | 5.74M | 2.96M | 383.00K | 218.00K |
| Cash, Cash Equivalents and Short-Term Investments | 10.95M | 8.23M | 5.03M | 1.81M | 9.00K | 90.00K |
| Total Debt | 44.00K | 71.00K | 119.00K | 14.00K | 673.00K | 3.61M |
| Total Liabilities | 1.10M | 2.66M | 1.71M | 2.70M | 2.01M | 4.94M |
| Stockholders Equity | 10.28M | 6.01M | 4.03M | 259.00K | -1.63M | -4.72M |
Cash Flow | ||||||
| Free Cash Flow | -13.58M | -10.19M | -8.61M | -9.00M | -1.09M | -8.31M |
| Operating Cash Flow | -13.58M | -10.19M | -8.61M | -8.99M | -1.08M | -8.31M |
| Investing Cash Flow | -3.00K | -3.00K | 0.00 | -8.00K | -3.00K | -3.84M |
| Financing Cash Flow | 21.25M | 13.39M | 11.83M | 10.80M | 1.01M | 15.75M |
GRI Bio Technical Analysis
Negative
1.91
Price Trends
1.85
Negative
1.82
Negative
2.43
Negative
Market Momentum
-0.14
Positive
36.99
Neutral
20.93
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GRI, the sentiment is Negative. The current price of 1.91 is above the 20-day moving average (MA) of 1.74, above the 50-day MA of 1.85, and below the 200-day MA of 2.43, indicating a bearish trend. The MACD of -0.14 indicates Positive momentum. The RSI at 36.99 is Neutral, neither overbought nor oversold. The STOCH value of 20.93 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for GRI.
GRI Bio Risk Analysis
GRI Bio disclosed 55 risk factors in its most recent earnings report. GRI Bio reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
GRI Bio Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
54 Neutral | $3.21M | -0.03 | -134.03% | ― | ― | 93.96% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
| ― | $1.96M | -0.12 | -144.23% | ― | ― | 86.26% | |
43 Neutral | $7.47M | -0.39 | -134.73% | ― | -60.74% | 66.05% | |
33 Underperform | $2.13M | -0.05 | -91.95% | ― | -51.33% | 99.22% |
* Healthcare Sector Average
GRI
GRI Bio
1.47
-55.37
-97.41%
OGEN
Oragenics
0.41
-0.87
-67.81%
INM
InMed Pharmaceuticals
1.36
-0.67
-33.00%
KTTA
Pasithea Therapeutics Corp
0.49
-0.24
-33.29%
ONCO
Onconetix
0.44
-167.14
-99.74%
GRI Bio Corporate Events
Business Operations and StrategyProduct-Related Announcements
GRI Bio Reports Positive Phase 2a IPF Biomarker Data
Positive
Sep 8, 2026
On September 8, 2026, GRI Bio reported new translational biomarker data from its Phase 2a study of GRI-0621, an oral tazarotene candidate for idiopathic pulmonary fibrosis, showing positive signals across clinical and biological endpoints. The dat...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.